Malignant Pleural Mesothelioma First-line Treatment Clinical Observation Research

Objects:Retrospective analysis of pemetrexed(PEM)/cisplatin and gemcitabine(GEM)/cisplatin solution line treatment of malignant pleural mesothelioma(MPM)efficacy and safety of whether there is a difference.Methods:This topic collected in August 2010- August 2014 tumor hospital of Shanxi Province and shanxi medical university second clinical hospital oncology by pathological histology or pleural effusion cytology diagnosis for malignant pleural mesothelioma(MPM), and accords with the standard set of 31 cases of patients, divided into two groups according to different chemotherapy regimens, PEM group: pemetrexed/cisplatin17 cases, the GEM group: gemcitabine/cisplatin 14 cases.By gathering the treatment efficacy of patient information, compared two groups of the objective of efficient treatment, disease control rates, adverse reaction and the median survival of disease progression, two schemes to deduce a line of the clinical efficacy of treatment of MPM.Results :PEM and GEM group objective efficient ORR between the two groups(35.2%VS28.5 %), disease control rates DCR(64.7% VS 57.1%), the difference between the two groups using the chi-square test, objective and efficient(chi-square = 0.001, P =0.990, P > 0.05), disease control rates(chi-square = 0.185, P = 0.952, P > 0.05) results no statistical significance.Progress in the median disease-free surial m PFS(5.5 months VS6.2) difference between the two groups after the Log- rank method significance test,the result has no statistical significance(chi-square = 0.639, P = 0.424, P > 0.05).Two groups of treatment of adverse reactions mainly for nausea, vomiting and hematology toxicity;Such as: white blood cells, decreased platelet, anemia.The GEM hematology incidence of adverse reactions than PEM group, but using the chi-square the adverse reactions of difference between two groups has no statistical significance(P > 0.05).Conclusion:Gemcitabine/cisplatin scheme first-line treatment of malignant pleural mesothelioma(MPM) of the efficacy and safety compared with pemetrexed/cisplatin did not see obvious difference.